ClinicalTrials.gg
RecruitingNCT06714383Updated Dec 3, 2024

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

A Phase 2 interventional study of Trilaciclib and Pirarubicin in Osteosarcoma, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
14 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Osteosarcoma by Peking University People's Hospital — 5 open to participants now, 7 under way, none of them phase 3. Osteosarcoma · Peking University People's Hospital.

Planned enrollment
8th of 12
50 · median 56
Started
2024
with 2 others
Phase 2
5 of 26
1 open now
Registered
21st of 26
by date

Among the 26 studies in Osteosarcoma by Peking University People's Hospital, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 in phase 2, and was the 21st registered.

Osteosarcoma

488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.

Browse Osteosarcoma studies →

Open to participants now

5 of the 26 studies in Osteosarcoma by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.

This study: 14 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Osteosarcoma by Peking University People's Hospital, or all of them as a file.
02

Study summary

To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.

Read the detailed description

Classic osteosarcoma is the most common primary bone malignancy. At present, osteosarcoma is usually treated with preoperative chemotherapy, surgical operation and postoperative chemotherapy. Treatment with preoperative chemotherapy is also known as neoadjuvant chemotherapy. Neoadjuvant chemotherapy has brought benefits to patients, but safety concerns are inevitable. Myelosuppression is a major factor affecting the compliance of patients treated by chemotherapy. Patients with chemotherapy-induced myelosuppression(CIM) have higher rates of infection, sepsis, bleeding, and fatigue, resulting in hospitalization, hematopoietic growth factor support, blood transfusions (red blood cells and/or platelets) and even death. In addition, CIM often leads to dose reduction and delayed administration, which limits the therapeutic dose intensity and therefore affects the anti-tumor efficacy of chemotherapy.

Currently, there are no approved treatments in osteosarcoma to prevent chemotherapy-induced cell damage. Although some treatments may help to address CIM when it occurs such as blood transfusions and growth factors, these treatments are pedigree specific, being used after hematopoietic stem progenitor cells damage and could bring additional toxicity.

Trilaciclib is a highly effective, selective and temporarily reversible inhibitor of CDK4/6. The proliferation of bone marrow hematopoietic stem cells depends on CDK4/6 activity. Bone marrow hematopoietic stem cells are blocked in the G1 phase of the cell cycle after exposure to Trilaciclib before chemotherapy is given.

Therefore, this study is conducted to evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.

03

Conditions studied

  • Osteosarcoma

Browse trials for

04

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written signed;
  2. Classic osteosarcoma confirmed by histopathology (high grade);
  3. Newly diagnosed stage Ⅱ-Ⅲ based on Enneking staging criteria;
  4. Planned to receive chemotherapy;
  5. on CT by 1.1.
  6. No antitumor system therapy received;
  7. 0-1
  8. Adequate organ function.
  9. Females of as well as males and their partners must agree to use an effective form of during the study and for 6 months following the last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  1. History of of other type;
  2. Allergic to study agent;
  3. History of psychotropic substance abuse, alcohol or drug use;
  4. The researchers considered inappropriate to join the study of any cause.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Trilaciclib Arm

    Neoadjuvant therapy of adding Trilaciclib to Pirarubicin and Lobaplatin

    Drug: Trilaciclib · Drug: Pirarubicin · Drug: Lobaplatin

  • Sham comparator
    Control Arm

    Neoadjuvant therapy of Pirarubicin and Lobaplatin

    Drug: Pirarubicin · Drug: Lobaplatin

Interventions

  • Trilaciclib: 240mg/m2, IV, within 4 hours before each chemotherapy agent infused.

    Also known as: Cosela

  • Pirarubicin: 60 mg/m2,IV,d1-2

  • LobaplLatin: 40 mg/m2,,IV,d1

06

What researchers measure

Primary outcomes

  1. Incidence of grade 3/4 neutropenia

    Incidence of grade 3/4 neutropenia up to 30 days

    Time frame: up to 30 days

Secondary outcomes

  1. Duration of grade 3/4 neutropenia

    Duration of grade 3/4 neutropenia up to 30 days

    Time frame: up to 30 days

  2. Incidence of grade 3/4 thrombocytopenia

    Incidence of grade 3/4 thrombocytopenia up to 30 days

    Time frame: up to 30 days

  3. Incidence of grade 3 or 4 anemia

    Incidence of grade 3 or 4 anemia up to 30 days

    Time frame: up to 30 days

  4. Incidence of febrile neutropenia

    Incidence of febrile neutropenia up to 30 days

    Time frame: up to 30 days

  5. Usage of granulocyte colony-stimulating factor (G-CSF)

    Utilization rate of granulocyte colony-stimulating factor (G-CSF) up to 30 days

    Time frame: up to 30 days

  6. Usage of Thrombopoietin (TPO)

    Utilization rate of Thrombopoietin (TPO) up to 30 days

    Time frame: up to 30 days

  7. Usage of Erythropoietin (ESA)

    Utilization rate of Erythropoietin (ESA) up to 30 days

    Time frame: up to 30 days

  8. Incidence of platelet transfusion

    Incidence of platelet transfusion up to 30 days

    Time frame: up to 30 days

  9. Incidence of red blood cell transfusion

    Incidence of red blood cell transfusion up to 30 days

    Time frame: up to 30 days

  10. Usage of ferralia

    Utilization rate of ferralia up to 30 days

    Time frame: up to 30 days

  11. chemotherapy dose reduction of any cause

    chemotherapy dose reduction rate of any cause up to 30 days

    Time frame: up to 30 days

  12. AE adverse event adverse event adverse event

    adverse event

    Time frame: up to 30 days

  13. SAE

    serious adverse event serious adverse event serious adverse event Serious Adverse Event

    Time frame: up to 30 days

  14. Termination of treatment caused by AE/SAE

    Termination of treatment rate caused by AE/SAE

    Time frame: up to 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2025, 8 months after the start.

Of 72 non-industry phase 2 interventional studies under Osteosarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 8 months is below that.

Counting every sponsor, half of 76 studies reached it within 65 months; a quarter within 40 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2024
First posted
Dec 3, 2024
StartActual
Nov 13, 2024
Primary completionEst.
Jul 2025
CompletionEst.
Nov 2025
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06714383
Responsible party
Tang Xiaodong (Dr., Peking University People's Hospital) — Principal investigator
First posted
Dec 3, 2024
Start date
Nov 13, 2024
Primary completion
Jul 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Dec 3, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trilaciclib

Start the discussion